---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-205006"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:24:58.112822+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Q32 Bio reports Q1 2026 net loss of $7.6M; bempikibart trial on track for mid-2026 data

## Summary
- Cash $50.8M at Mar 31; plus $14.2M ATM proceeds post-Q and milestone payments fund into 1H 2028.
- Net loss $7.6M ($0.54 EPS) vs $11.0M ($0.90) in Q1 2025.
- Bempikibart Part B SIGNAL-AA 36-wk topline data readout on track for mid-2026; first OLE patient dosed.
- Completed $10.5M registered direct offering in Feb 2026 (1.7M shares/pre-funded warrants at $3.90).
- R&D expenses fell to $3.2M from $7.1M due to headcount reduction and ADX-097 sale.

## SEC filing metadata
- accession: 0001193125-26-205006
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000119312526205006/0001193125-26-205006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000119312526205006/qttb-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-205006
- JSON: https://secwatch.observer/filing/0001193125-26-205006.json
- Plain text: https://secwatch.observer/filing/0001193125-26-205006.txt

## Source-grounded claims
- claim_id: cb541179af3d4151c0532f6aa5ef7e966fbf056c
  claim: Q32 Bio Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $7.6 million, or $0.54 basic and diluted net loss per share, EPS $0.54 basic and diluted net loss per share.
  evidence_excerpt: Net loss was $7.6 million, or $0.54 basic and diluted net loss per share, for the three months ended March 31, 2026, compared to net loss of $11.0 million, or $0.90 basic and diluted net loss per share, for the three months ended March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661998/000119312526205006/0001193125-26-205006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.